Market capitalization | $762.64m |
Enterprise Value | $482.37m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.55 |
P/S ratio (TTM) P/S ratio | 11.94 |
P/B ratio (TTM) P/B ratio | 1.58 |
Sales growth (TTM) Sales growth | 22.14% |
Turnover (TTM) Turnover | $63.88m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
8 Analysts have issued a CureVac N.V. forecast:
8 Analysts have issued a CureVac N.V. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 64 64 |
22%
22%
|
|
Gross income | -117 -117 |
30%
30%
|
|
EBITDA | -294 -294 |
-
|
EBIT (operating result) EBIT | -322 -322 |
4%
4%
|
Net profit | -296 -296 |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Head office | Netherlands |
CEO | Alexander Zehnder |
Employees | 1,172 |
Founded | 2020 |
Website | www.curevac.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.